Hyaluronidase (Human Recombinant)
A recombinant human form of hyaluronidase that degrades hyaluronan in the subcutaneous space, used to facilitate the delivery of subcutaneous injections of large biologics such as trastuzumab and rituximab, allowing what would otherwise require intravenous infusion to be given as a brief subcutaneous injection. This enables more convenient outpatient drug administration. It reduces hyaluronan-mediated resistance to fluid flow in tissues to allow drug distribution.
Wirkmechanismus
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A recombinant human form of hyaluronidase that degrades hyaluronan in the subcutaneous space, used to facilitate the delivery of subcutaneous injections of large biologics such as trastuzumab and rituximab, allowing what would otherwise require intravenous infusion to be given as a brief subcutaneous injection. This enables more convenient outpatient drug administration. It reduces hyaluronan-mediated resistance to fluid flow in tissues to allow drug distribution.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Hyaluronidase (Human Recombinant) is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201718. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hyaluronidase-human-recombinant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hyaluronidase-human-recombinant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hyaluronidase-human-recombinant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hyaluronidase-human-recombinant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hyaluronidase-human-recombinant"></drugfyi-drug>